A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Recruiting
Observational Study
Psoriasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Janssen-Cilag Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
* Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
* Participants who, b…
Contacts